Vicore Pharma Holding AB (publ) (FRA:6Y4)

Market Cap	269.95M +78.7%
Revenue (ttm)	352.70K -96.5%
Net Income	-44.12M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.8950
Previous Close	0.8960
Day's Range	0.8950 - 0.8950
52-Week Range	0.5840 - 1.1820
Beta	n/a
RSI	51.22
Earnings Date	May 6, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 36
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6Y4

Financial Performance

In 2025, Vicore Pharma Holding AB's revenue was 3.82 million, a decrease of -96.51% compared to the previous year's 109.35 million. Losses were -477.47 million, 183.1% more than in 2024.

Financial numbers in SEK